Sign in
4

Changes in Ownership

Cartesian Therapeutics, Inc. Filed Acc 0001062993-23-020923

Options or other derivatives

  • Chief Scientific Officer acquired 4,276.45 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Jewell Christopher M Chief Scientific Officer 2023-11-13 Grant or award · Stock Option (Right to Buy) +4,276.45 4,276.45 D
Loading xslF345X05/form4.xml…